Blogs about: Xx Oncology
Featured Blog
AmpliMed Corp.: Series C $22.0M
AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malignant melanoma and pancreatic cancer closed on $5M traunche of a $22M Series C financing. Participant… more →
OnBioVC
AmpliMed Corp.: Series C $22.0M
arubenstein wrote 1 year ago: AmpliMed (Tucson, AZ) a clinical-stage pharmaceutical company with Phase II lead compounds for malig … more →
ChemoCentryx, Inc.: Series D $29.9M
arubenstein wrote 2 years ago: ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases … more →
Cylene Pharmaceuticals, Inc.: Series C $44M
arubenstein wrote 2 years ago: Cylene Pharmaceuticals (San Diego, CA) a small molecule oncology drug discovery and development comp … more →
